Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17806
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHollands, Simone-
dc.contributor.authorLim, Yen Ying-
dc.contributor.authorLaws, Simon M-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorPietrzak, Robert H-
dc.contributor.authorHarrington, Karra-
dc.contributor.authorPorter, Tenielle-
dc.contributor.authorSnyder, Peter-
dc.contributor.authorAmes, David-
dc.contributor.authorFowler, Christopher-
dc.contributor.authorRainey-Smith, Stephanie R-
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorSalvado, Olivier-
dc.contributor.authorRobertson, Joanne-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorMaruff, Paul-
dc.date.accessioned2018-05-28T06:13:54Z-
dc.date.available2018-05-28T06:13:54Z-
dc.date.issued2017-
dc.identifier.citationJournal of Alzheimer's disease : JAD 2017; 57(2): 411-422en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17806-
dc.description.abstractIn cognitively normal (CN) older adults, carriage of the apolipoprotein E (APOE) ɛ4 allele is associated with increased risk for dementia of the Alzheimer type (AD-dementia). It is unclear whether this occurs solely through APOEɛ4 increasing amyloid-β (Aβ) accumulation or through processes independent of Aβ. To determine the extent and nature to which APOEɛ4 increases risk for clinical disease progression in CN older adults. Data from the total (n = 765) and Aβ-imaged (n = 423) CN cohort in the Australian Imaging, Biomarker and Lifestyle (AIBL) Study of Ageing was analyzed using Cox proportional hazard models to estimate ɛ4 risk for clinical disease progression over a 72-month follow-up. With Aβ status unknown and risk from demographic characteristics controlled, ɛ4 carriage increased risk for clinical disease progression over 72 months by 2.66 times compared to risk of non-ɛ4 carriage. Re-analysis with Aβ status included showed that abnormally high Aβ increased risk for clinical disease progression over 72 months by 2.11 times compared to risk of low Aβ. However, with Aβ level known, ɛ4 carriage was no longer predictive of clinical disease progression. In CN older adults, the risk of ɛ4 for clinical disease progression occurs through the effect of ɛ4 increasing Aβ levels.en
dc.language.isoeng-
dc.subjectAlzheimer type dementiaen
dc.subjectAlzheimer’s diseaseen
dc.subjectamyloid-βen
dc.subjectapolipoprotein E4en
dc.subjectpositron emission tomographyen
dc.titleAPOEɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Alzheimer's disease : JADen
dc.identifier.affiliationCogstate Ltd., Melbourne, Victoria, Australiaen
dc.identifier.affiliationLa Trobe University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australiaen
dc.identifier.affiliationSir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, WA, Australiaen
dc.identifier.affiliationCo-operative Research Centre for Mental Health, http://www.mentalhealthcrc.comen
dc.identifier.affiliationThe Florey Institute, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USAen
dc.identifier.affiliationDepartment of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USAen
dc.identifier.affiliationAcademic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew, Victoria, Australiaen
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Victoria, Australiaen
dc.identifier.affiliationCommonwealth Scientific Industrial Research Organization (CSIRO) Preventative Health National Research Flagship, Australian e-Health Research Centre-BiaMedIA, Brisbane, QLD, Australiaen
dc.identifier.doi10.3233/JAD-161019en
dc.type.contentTexten
dc.identifier.orcid0000-0003-3910-2453en
dc.identifier.pubmedid28234254-
dc.type.austinJournal Article-
local.name.researcherMasters, Colin L
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

50
checked on Dec 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.